New treatment options for myelofibrosis patients with a high risk of anemia?

Myelofibrosis is considered one of the most complex myeloproliferative neoplasms – with high symptom burden, progressive cytopenia and limited treatment options – with anemia in particular presenting a clinical challenge that often worsens with conventional JAK inhibition. A multicenter study published in August 2025 by an Italian research team now provides care-related evidence for momelotinib as a potential disease-modifying option to restore erythropoiesis and control spleen-related symptoms.